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Ramoplanin is a glycolipodepsipeptide antibiotic obtained from fermentation of
Actinoplanes sp. ATCC 33076 that exhibits activity against clinically important
multi-drug-resistant, Gram-positive pathogens including vancomycin-resistant
Enterococcus (VRE), methicillin-resistant Staphylococcus aureus (MRSA), and
vancomycin-intermediate resistant Clostridium difficile. It disrupts bacterial cell wall
through a unique mechanism of action by sequestering the peptidoglycan intermediate
Lipid II and therefore does not show cross-resistance with other antibiotics. However,
while demonstrating excellent antimicrobial activity in systemic use in animal models
of infection, ramoplanin presents low local tolerability when injected intravenously.
As a consequence of this limitation, new derivatives are desirable to overcome this
issue. During a natural product screening program developed to discover compounds
that disrupt bacterial cell wall synthesis by inhibiting peptidoglycan transglycosylation
through binding to the intermediate Lipid II, 49 actinomycete strains were identified by
HR-LCMS as producers of ramoplanin-related compounds. The producing strains were
isolated from environmental samples collected worldwide comprising both tropical and
temperate areas. To assess the diversity of this microbial population, the 49 isolates
were initially identified to the genus level on the basis of their micromorphology, and 16S
sequencing confirmed the initial identification of the strains. These analyses resulted
in the identification of members of genus Streptomyces, as well as representatives
of the families Micromonosporaceae, Nocardiaceae, Thermomonosporaceae, and
Pseudonocardiaceae, suggesting that the production of ramoplanins is relatively
widespread among Actinomycetes. In addition, all of these isolates were tested against
a panel of Gram-positive and Gram-negative bacteria, filamentous fungi, and yeast
in order to further characterize their antimicrobial properties. This work describes
the diversity of actinomycete strains that produced ramoplanin-related compounds,
and the analysis of the antimicrobial activity exhibited by these isolates. Our results
strongly suggest the presence of new ramoplanin-analogs among these actinomycete
producers.
Keywords: high-throughput screening, microbial natural products, antibacterial activity, actinomycetes,
ramoplanin, peptidoglycan intermediate Lipid II
de la Cruz et al. Production of Ramoplanin and Ramoplanin Analogs by Actinomycetes
INTRODUCTION
New antibiotics with new mechanisms of action are urgently
needed because clinically significant bacterial pathogens have not
only acquired resistance to nearly all existing antibiotics, but also
increasingly exhibit multi-drug resistance (Gerits et al., 2016).
Considering that the present antibiotic therapies have become
increasingly inefficient, new technologies are required to identify
and develop novel classes of antibacterial agents.
While searching for novel antibacterial leads, an attractive
alternative to the classical target-based approach is the use of
promoter-inducible reporter assays that are amenable to high-
throughput screening. These assay systems are based on cells that
carry reporters such as β-galactosidase or luciferase genes fused to
promoters that specifically respond to certain types of antibiotic
stress (Shapiro and Baneyx, 2002; Sun et al., 2002; Fischer
et al., 2004). Those genetically modified strains are particularly
advantageous for high-throughput assay systems considering the
low compound concentrations that they require. The selective
induction of the reporter fusion indicates that a compound is at
least perturbing the pathway of interest as part of its biochemical
impact (Fischer et al., 2004).
DNA microarray analysis of the response of Bacillus subtilis
treated with sublethal concentrations of the cell wall antibiotic
bacitracin revealed the presence of overlapping regulons
controlled by alternative sigma factors and two component
systems. One operon strongly induced by bacitracin, which was
identified by John Helmann’s laboratory at Cornell University,
contains the genes liaIHGFSR (liaRS stands for lipid II cycle
interfering antibiotic response Regulator and Sensor). The β-
galactosidase gene lacZ was placed downstream of the promoter
for this operon (PliaI) such that induction of the operon by
bacitracin or other compounds that have the same effect on
the liaRS two component regulatory system will induce the
production of β-galactosidase. This can then be monitored as an
indication of antibiotic action that is impacting this liaRS system
(Cao et al., 2002; Mascher et al., 2003).
Lipid II is a membrane-bound cell wall precursor which
performs the cycle of peptidoglycan “building block”
translocation. The efficiency of targeting Lipid II as an
antibacterial strategy is highlighted by the fact that it is the
target for at least four different classes of antibiotics (lantibiotics,
mannopeptimycins, ramoplanin, and vancomycin). Since this
pathway is limited to prokaryotes and low toxicity is expected,
it is highly desirable to discover novel structural classes that
interfere with it. Moreover, the emergent problem of bacterial
resistance to drugs such as vancomycin has led to increasing
interest in the therapeutic potential of other compounds that
target Lipid II (Donadio et al., 2002).
A natural product screening program was developed to detect
inhibitors that interfere with stage II peptidoglycan biosynthesis.
This screening approach called “LiaRS assay” allowed the
identification of positive controls such as ramoplanin.
Ramoplanin is a lipoglycodepsipeptide antibiotic derived
from Actinoplanes spp. ATCC 33076 and was first isolated as
a complex of three closely related components A1, A2, and
A3 (A1, 6–12%; A2 72–86%; A3 8–14%) in which A2 was the
most abundant (Cavalleri et al., 1984). The structural difference
is in the length of the N-terminal acyl chain. Ramoplanin A2
exhibits activity against clinically important Gram-positive
bacteria including vancomycin-resistant Enterococcus sp. (VRE),
methicillin-resistant S. aureus (MRSA) and vancomycin-
intermediate resistant Clostridium difficile (Finegold et al., 2004;
Peláez et al., 2005). Preclinical studies have also demonstrated
that ramoplanin exerts a rapid bactericidal effect on S. aureus
biofilms (Schmidt et al., 2010) and that a clinical vancomycin-
resistant S. aureus strain containing the vanA gene was
susceptible to ramoplanin (Bozdogan et al., 2003). Recently,
it has been reported (by Nanotherapeutics) to have additional
activity against C. difficile spores, both in vitro and in an animal
model (Jabes et al., 2014). Ramoplanins have a uniquemechanism
of action that disrupts bacterial cell wall by interfering with late-
stage transglycosylation cross-linking reactions in peptidoglycan
biosynthesis. Ramoplanin A2 acts by sequestering the Lipid
Intermediate II, which keeps this substrate from accurate use
in downstream reactions catalyzed by transglycosylases that
produce mature peptidoglycan polymer. This antibiotic works
at a site complementary to vancomycin and shows no cross-
resistance with other glycopeptides. At present, ramoplanin
is being developed for the targeted prophylaxis of recently
treated patients with C. difficile infection (CDI) at high risk for
infection relapse. Twelve Phase I studies, two Phase II studies
(one in CDI and one in VRE) as well as one Phase III study (in
VRE) have been conducted (http://www.nanotherapeutics.com/
ramoplanin/). Although Phase III study was not completed.
Results presented in this paper illustrate that this screening
approach allowed us to detect actinomycete strains that
produced ramoplanin-related components. The diversity of those
actinomycete strains is described, along with the analysis of
the antimicrobial activity exhibited by these isolates. Likewise,
HR-LCMS analyses strongly suggest the presence of new
ramoplanin-analogs among these actinomycete producers and
current large scale fermentations and purifications are being
performed for the identification of these novel antimicrobials.
To our knowledge, this is the first report that the production of
ramoplanin-type natural products is relatively widespread within
Actinomycetes.
MATERIALS AND METHODS
Morphological Identification of
Actinomycete Strains
Actinomycetes were tentatively identified to the genus or
family level after direct observation of the microscopic
morphology (400× and 1000× magnification with long distance
range objectives) of the vegetative and aerial mycelium and
characteristic sporulating structures developed upon growth on
water agar for 21 days at 28◦C (Goodfellow et al., 1984, 2012).
DNA Extraction and Molecular
Characterization
Total genomic DNA from the actinomycetes used in this study
was purified as previously described (Innis et al., 1990) from
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strains grown in ATCC-2 liquid medium [0.5% yeast extract
(Difco, Franklin Lakes, NJ, USA), 0.3% beef extract (Difco),
0.5% peptone (Difco), 0.1% dextrose (Difco), 0.2% starch from
potato (Panreac, Barcelona, Spain), 0.1% CaCO3 (E. Merck,
Darmstadt, Germany), and 0.5% NZ amine E (Sigma, St Louis,
MO, USA)]. PCR primers fD1 and rP2 were used for amplifying
the nearly full-length 16S ribosomal RNA genes of the strains
(Weisburg et al., 1991). PCR products were sent to Secugen
(http://www.secugen.es/) for sequencing, and were used as a
template in sequencing reactions using the primers fD1 and
rP2, and 1100R and 926F (Lane, 1991). Partial sequences
were assembled and edited using the Assembler contig editor
component of Bionumerics (ver 5.10) analysis software (Applied
Maths NV, Sint-Martens-Latem, Belgium).
The identification of the closest match sequences was
performed against the database of type strains with validly
published prokaryotic names (Chun and Int, 2007) which
was implemented at the EzTaxon server (http://ezbiocloud.net/
eztaxon; Kim et al., 2012).
Characterization of Actinomycete Strains
The soil samples used for the isolation of the 49 actinomycete
strains were collected worldwide comprising both tropical and
temperate areas: Costa Rica, French Guyana, Mexico, New
Caledonia, South Africa, Spain, and Sri Lanka, including different
ecological habitats like agricultural soils, riverbeds, lakes, ponds,
swamps, dunes, tropical and sempervirent forests, savanna soil,
and rhizospheres.
The strains were tentatively identified on the basis of their
macro and micro-morphology and the genus assignment of 39
strains was confirmed by 16S rDNA gene sequencing. The most
abundant taxonomic group was the family Micromonosporaceae
(71.4%) with 34 strains identified as members of the genus
Micromonospora and 1 strain of Actinoplanes. The remaining
strains were,identified as Nocardia (3 strains), Streptomyces (3
strains), Actinomadura (1 strain), Amycolatopsis (1 strain), and
Lechevalieria (1 strain). Five strains could not be assigned to
any genus and were morphologically identified as filamenting
Actinobacteria (Table 2).
Natural Products Extract Library
Generation
Bacteria and fungi were grown in complex liquid media
containing different amounts of nutrient sources: carbon sources
(e.g., monosaccharides, disaccharides), complex carbon sources
(e.g., wheat flour, soluble starch), nitrogen sources, and mineral
salts sources (R. Tormo et al., 2003). The secondary metabolites
in the broths were extracted with acetone (1:1) and shaking in
an orbital shaker for 1 h. The extracts were then centrifuged
at 1,500 × g for 15min. 1.5mL of DMSO were added to
aliquots of 15mL and the resulting mixture was evaporated
in a Turbovap equipment until half of the volume remained,
∼7.5mL, to a final crude concentration of 1xWBE (whole broth
equivalents) and 20% DMSO. Five-hundred microliters of these
crude extracts were stored at −20◦C in 96-well ABgene plates
until needed.
LiaRS Screening Assay
The screening assay was performed against two Bacillus subtilis
strains. The lacZ gene was fused to the liaI promoter (P liaI)
in both strains such that induction of this promoter results in
the production of β-galactosidase. One strain contains the lacZ
fusion and additionally has a kanamycin insertion into the liaR
gene that inactivates liar. The P liaI-lacZ fusions were licensed
from Cornell University by Merck & Co., Inc. (Mascher et al.,
2003, 2004). Strains belong to the Merck culture collection with
the following codes: HB0950 (MB5826, CU1065 SPb P-liaI74-
cat-lacZ) and HB0953 (MB5827, CU1065 SPb P-liaI74-cat-lacZ
liaR::kan). Afterwards, Merck & Co., Inc. donated both of them
to FoundationMEDINA. Strain HB0953 contains the lacZ fusion
but additionally has a kanamycin insertion into the liaR gene
which inactivates liaR. B. subtilis strain HB09050 or HB09053
was incubated to stationary phase in LB (1% NaCl) at 37◦C and
220 rpm. The culture was adjusted to an optical density of 0.25
at a wavelength of 600 nm. Then, 100-mL of LB agar (1% NaCl)
that contained 250 µg/ml of X-gal was inoculated with 1mL of
bacteria. The inoculated agar was poured into a NUNC bioassay
plate (245 × 245mm). After the agar solidified, the plates were
dried in a laminar-flow hood for 15min. After that, 0.02mL
drops of natural product extract were placed on the surface of the
agar and the plates were allowed to dry in a laminar-flow hood for
15min. The plates were incubated for 18 h at 37◦C. They were
scored for zones of inhibition and for hydrolysis of X-gal (blue
precipitate). Bacitracin (50 mg/mL) was used as positive control
of the assay while vancomycin (0.5mg/mL) was used as negative
control.
In vitro Antimicrobial Activity
MIC Determination Assays
MICs values of samples against a panel of strains from
MEDINA collection which are: Staphylococcus aureus (CL 860),
Haemophillus influenzae (CLB 21526), Pseudomonas aeruginosa
(PAO-1), Escherichia coli (ATCC 25922), Enterococcus faecalis
(ATCC 29212), and Candida albicans (MY 1055) strains were
determined by the microdilution technique in accordance with
the guidelines of the National Committee for Clinical Laboratory
Standards (NCCLS, 2007) using inocula of 1 × 105–5 × 105
CFU/mL. Serial dilutions of extracts were performed to assess
growth inhibition. Microtiter plates were incubated at 35◦C for
20–24 h. Cell growth was monitored by comparing the optical
density between the time of treatment and after incubation
time. The lowest concentration causing 90% inhibition microbial
growth was defined as the MIC.
Aspergillus fumigatus Agar-Based Assay
The A. fumigatus (MF5668: ATCC13073) stock conidial
suspension was adjusted by quantitative colony counts at 3.5 ×
109 CFU/mL. The conidial suspension was diluted into Yeast
Nitrogen Base broth (YNB, 6.75 g L−1 yeast nitrogen base) to
65% transmittance at 660 nm. Then, 10mL of this inoculum
broth was added to 1 L of Yeast Nitrogen Base-Dextrose and
20mL of the seeded agar media were poured into Omnitray
plates. Once the agar solidified, the plates were dried in a laminar
flow hood for 15min. After this time 10 µL of each extract
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were distributed on the surface of agar plates and incubated at
29◦C for 18 h. Finally, the halos of inhibition were measured.
Amphotericin B (0.25mg/mL) was used as a positive control for
this assay.
Macromolecular Labeling Assay
The labeling reaction contained 0.05mL of a log phase culture
of Bacillus subtilis HB0950 in nutrient broth that contained 1%
NaCl, 0.025mL of two-fold concentrated nutrient broth (2%
NaCl) that contained 7.5 mCi/L of L-[2, 3-3H]-aspartic acid, 5
mCi/L of [2-14C]-thymidine, 100mg/L of chloramphenicol or
0.8 mg/L of rifampicin and 0.025mL of inhibitor (1xWBE). The
samples were incubated 37◦C on a microtiter plate shaker. After
30min, 0.025mL of 25% TCA was added to stop radioactive
incorporation. The TCA-insoluble material was collected on a
glass microfiber filtermat with a Skatron Cell Harvester. The
filtermat was washed with distilled H2O and dried under a stream
of hot air. Radioactivity was measured in a Betaplate Scintillation
Counter.
Liquid Chromatography-High Resolution
Mass Spectrometry and Data Analysis
Two micro liters of the extracts were analyzed by LC-HRMS.
Analysis was performed on an Agilent (Santa Clara, CA) 1100
single Quadrupole LC-MS, using a Zorbax SB-C8 column (2.1
× 30 mm), maintained at 40◦C and with a flow rate of 300
ul/min. Solvent A consisted of 10% acetronitrile and 90% water
with 0.01% trifluoroacetic acid and 1.3mM ammonium formate,
while solvent B was 90% acetronitrile and 10% water with
0.01% trifluoroacetic acid and 1.3mM ammonium formate. The
gradient started at 10% B and went to 100% B in 6min, kept at
100% B for 2 min, and returned to 10% B for 2min to initialize
the system. Full diode array UV scans from 100 to 900 nm were
collected in 4 nm steps at 0.25 s/scan.
HRMS data was acquired in a Thermo Finnigan LTQ-FT with
the standard Ion Max API source (without the sweep cone) and
ESI probe. Three scan events were used. The ion trap was scanned
from 150 to 2,000 first in negative ion mode and then in positive
ion mode. The FT was scanned from 200 to 2,000 in the positive
ion mode only. In all cases the SID was set to 18 volts to try to
reduce multiple ion clusters.
Data were analyzed with Apex software. The standard
conditions were; peak width/resolution is set to 100,000
resolution at mass 400, MS search tolerance set between 0.008
and 0.003 Da. Apex software is a product from Sierra Analytics
(Modesto, CA).
RESULTS
Validation of LiaRS Assay
The LiaRS (Lipid II cycle interfering antibiotic response
Regulator and Sensor) two-component system (Figure 1) is
one of several antibiotic-sensing systems that coordinate the
genetic response to cell wall active antibiotics. Upon addition of
inhibitors of stage II peptidoglycan synthesis, LiaRS autoregulates
the liaIHGFSR operon. The lia promoter responds strongly
and specifically to antibiotics that interfere with the lipid
FIGURE 1 | LiaRS—Lipid II cycle interfering antibiotic response
Regulator and Sensor: Two-component antibiotic sensing system in
Bacillus subtilis that co-ordinates genetic response to inhibitors of
peptidoglycan synthesis that interfere with the lipid II cycle.
Background strain: Bacillus subtilis CU1065; HB0950: lacZ fusion; HB0953:
lacZ fusion, kanR insertion (liaR gene disrupted). LiaRS autoregulates the
liaIHGFSR operon. Induction of the liaIH operon mediated by the
two-component liaRS sensor/regulator system. Specificity associated with
liaRS. lacZ inserted downstream from PliaI. Induction results in production of
β-galactosidase. Induction of β-galactosidase in B. subtilis HB0953 indicates
that induction was not due to an inhibitor of peptidoglycan synthesis.
II cycle. The induction of β-galactosidase by these types of
antibiotics is detected with X-gal, which turns blue when
hydrolyzed by β-galactosidase. It is possible to differentiate
specific interference of the lipid II cycle because specific
inhibitors will induce the production of β-galactosidase in
strain HB0950 but not in HB0953, in which the liaR gene
has been disrupted. The LiaRS system and the two Bacillus
strains have been previously described by Mascher et al.
(2004).
B. subtilis HB0950 (MB5826, CU1065 SPb P-liaI74-cat-lacZ)
produces β-galactosidase in response to the induction of liaI by
certain cell-wall active antibiotics. B. subtilis HB0953 (MB5827,
CU1065 SPb P-liaI74-cat-lacZ liaR::kan) is a liaR knock-out
mutant. It is also capable of synthesizing β-galactosidase, but not
in response to the liaIHGFSR operon.
In B. subtilis HB0950, the lacZ gene has been fused
to the liaI promoter (PliaI) such that induction of this
promoter results in the production of β-galactosidase. This
production can be detected when this strain is grown on
Luria agar (LA) medium containing either 5-bromo-4-chloro-
3-indolyl-β-D-galactoside (X-gal) or 3,4-cyclohexenoesculetin-
β-D-galactopyranoside (S-gal) in the presence of an inducer.
Detection of β-galactosidase activity in HB0950 has been
shown to be 150–200-fold over background in the presence
of bacitracin, ramoplanin, and nisin, and ∼35-fold over
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background in the presence of vancomycin (Mascher et al., 2004).
Other antibiotics affecting protein synthesis (chloramphenicol,
kanamycin, spectinomycin, streptomycin, tetracycline), RNA
synthesis (rifampicin), and peptidoglycan synthesis (β-lactams,
moenomycin, D-cycloserine), did not induce β-galactosidase
production; neither did detergents (SDS, Triton) nor uncouplers
TABLE 1 | Non-inducers of liaI Expression and Inducers of liaI Expression.
Compound liaI Expression Disk diffusion assay response
Kanamycin Non-inducer Negative
Rifampicin Non-inducer Negative
Tetracycline Non-inducer Negative
Chloramphenicol Non-inducer Negative
Spectinomycin Non-inducer Negative
Streptomycin Non-inducer Negative
SDS Non-inducer Negative
Triton Non-inducer Negative
DNP Non-inducer Negative
Lysozyme Non-inducer Negative
Ampicillin Inducer Negative
Bacitracin Inducer Positive
Cepaholsporin Inducer Negative
D-cycloserine Inducer Negative
Moenomycin Inducer Negative
Nisin Inducer Positive
Penicillin G Inducer negative
Polymyxin B Inducer negative
Ramoplanin Inducer Positive
Tunicamycin Inducer Positive
Vancomycin Inducer Positive
Activity was assessed by the appearance of a blue ring around the edge of the zone of
inhibition on LB agar plates supplemented with X-Gal. (Compounds were tested in a range
concentration of 50–0.5mg/mL).
of oxidative phosphorylation (DNP, CCCP). The production of
β-galactosidase by HB0950 appears to be a specific response
to compounds that bind to or otherwise interfere with
recycling of lipid I in stage II peptidoglycan biosynthesis
(Table 1).
B. subtilis strain, HB0953, contains the lacZ fusion but
additionally has a kanamycin insertion into the liaR gene which
inactivates liaR. Since an intact two-component liaRS system is
required for induction of the liaIH operon, inactivation of this
system by kan insertion into liaR results in the inability of true
inducers of P liaI to turn on β-galactosidase production. On
X-gal medium, the LiaRS response appears to be very specific
for true inducers and no false positive responses on HB0950
have been observed. However, with S-gal, fluoroquinolones,
and cephalosporins produce a response on HB0950 that might
be interpreted as a weak positive. These can be differentiated
from true positives through the use of HB0953. On HB0953,
true positives such as bacitracin and ramoplanin give an
unambiguously negative response, while fluoroquinolones and
cephalosporins give the same weak positive response as they do
on HB0950.
Natural Products Screening for Lipid II
Inhibitors
A set of 37,000 natural products (NP) extracts (50% bacteria
and 50% fungi) were screened against the LiaRS assay described
above at a single concentration (1xWBE), giving a hit rate of
0.13%. As controls, extracts with bacitracin and vancomycin
were applied in each plate onto the agar surface (Figure 2).
Extracts that caused induction of β-galactosidase in B. subtilis
strain HB0950 were tested for specificity by re-testing them
against both strains HB0950 and HB0953. The blue response
was rated from 1 to 3 according to their intensity. A
total of 49 actinomycetes strains were authentic inducers of
LiaRS activity causing a blue response against HB0950 but
not against HB0953. The larger and bluer inhibition zones
FIGURE 2 | Example of the response of some active (blue ring response) extracts in the agar- based LiaRS assay (Nunc-plate).
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TABLE 2 | Taxonomy and number of strains isolated from both tropical and temperate countries.
Strain Origin Ecological habitats Family Closest neighbor (EzTaxon result) Similarity Accession
number
F-178,252 Mexico Soil Micromonosporaceae Actinoplanes ferrugineus 97.98 KY454560
F-151,217 French Guyana Rainforest Micromonospora chaiyaphumensis 99.35 KY454536
F-151,215 Micromonospora sp. (*)
F-175,917 Mexico Pond Micromonospora chaiyaphumensis 99.06 KY454552
F-179,413 Micromonospora chaiyaphumensis 99.85 KY454568
F-143,677 New Caledonia Savannah Micromonospora chaiyaphumensis 99.78 KY454532
F-182,202 South Africa Rhizosphere Micromonospora chaiyaphumensis 99.64 KY454570
F-182,239 Micromonospora chaiyaphumensis 99.64 KY454571
F-182,241 Micromonospora chaiyaphumensis 99.64 KY454572
F-188,416 Micromonospora chaiyaphumensis 99.64 KY454573
F-188,417 Micromonospora chaiyaphumensis 99.64 KY454574
F-188,442 Micromonospora chaiyaphumensis 99.63 KY454575
F-162,175 French Guyana Rainforest Micromonospora chersina 99.64 KY454541
F-140,177 New Caledonia Sempervirent forest Micromonospora sp. (*)
F-144,426 Micromonospora chersina 99.64 KY454533
F-149,663 Savannah Micromonospora chersina 99.72 KY454535
F-143,676 Micromonospora sp. (*)
F-169,627 Sri Lanka Mangrove Micromonospora chersina 99.71 KY454545
F-175,357 Micromonospora chersina 99.64 KY454551
F-177,720 Micromonospora chersina 99.78 KY454556
F-177,770 Micromonospora chersina 99.57 KY454557
F-177,777 Micromonospora chersina 99.71 KY454558
F-178,645 Micromonospora chersina 99.71 KY454563
F-178,647 Micromonospora chersina 99.71 KY454564
F-179,454 Micromonospora chersina 99.64 KY454569
F-151,222 French Guyana Rainforest Micromonospora endolithica 99.57 KY454537
F-170,297 South Africa Rhizosphere Micromonospora equina 99.41 KY454546
F-178,247 Mexico Soil Micromonospora fulviviridis 99.42 KY454559
F-179,400 Pond Micromonospora halotolerans 99.64 KY454567
F-161,233 South Africa Dune Micromonospora halotolerans 99.85 KY454540
F-168,651 Rhizosphere Micromonospora halotolerans 99.64 KY454542
F-169,254 Micromonospora inositola 99.43 KY454543
F-169,257 Micromonospora inositola 99.48 KY454544
F-170,386 Micromonospora inositola 99.5 KY454547
F-171,509 Micromonospora inositola 99.49 KY454548
F-146,703 New Caledonia Sempervirent forest Nocardiaceae Nocardia niigatensis 99.86 KY454534
F-161,197 South Africa Dune Nocardia testacea 99.64 KY454539
F-186,787 Rhizosphere Nocardia sp. (*)
F-117,410 Costa Rica Agricultural land Pseudonocardiaceae Amycolatopsis umgeniensis 99.71 KY454530
F-178,253 Mexico Soil Lechevalieria atacamensis 98.99 KY454561
F-177,328 Lake Streptomycetaceae Streptomyces atrovirens 99.62 KY454553
F-177,430 Soil Streptomyces atrovirens 99.57 KY454554
F-152,578 Spain River bed Streptomyces mirabilis 99.36 KY454538
F-151,073 French Guyana Rainforest Thermomonosporaceae Actinomadura sp. (*)
F-175,914 Mexico Pond Unidentified Unidentified (*)
F-161,198 South Africa Dune Unidentified (*)
F-161,203 Unidentified (*)
F-161,272 Unidentified (*)
F-171,173 Rhizosphere Unidentified (*)
(*) 16S rDNA gene sequence not available.
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were produced by a series of extracts within the group of
actinomycetes.
Characterization of Actinomycete Strains
The soil samples used for the isolation of the 49 actinomycete
strains were collected worldwide comprising both tropical and
temperate areas: Costa Rica, French Guyana, Mexico, New
Caledonia, South Africa, Spain, and Sri Lanka, including different
ecological habitats like agricultural soils, riverbeds, lakes, ponds,
swamps, dunes, tropical and sempervirent forests, savanna soil,
and rhizospheres.
The most abundant taxonomic group identified by
morphological analysis was the family Micromonosporaceae
(69.3%, 34 strains most in the genera Micromonospora). Also,
3 strains were assigned to Nocardia, 3 strains to Streptomyces,
1 strain to Actinomadura, 2 strains to Amycolatopsis, and 1
strain to Actinoplanes. A set of 5 strains could not be identified
(Table 2).
Evaluation of Antimicrobial Activity
Most of the extracts exhibited activity against Gram-positive
bacteria (S. aureus, Enterococcus faecalis). Their IC90-values
oscillated in a range of 0.06–0.015 WBE/mL, together with
some extracts which showed a IC90 value below 0.002 WBE/mL.
Contrary, none of the extracts displayed activity against
Gram-negative bacteria (Haemophilus influenzae, Pseudomonas
aeruginosa, Escherichia coli) or against Aspergillus fumigatus, nor
against Candida albicans. They showed MIC-values above the
first point of dilution (>0.06 WBE/mL) except for extract F-
144,426-C03-C01 that showed weak antifungal activity against C.
albicans giving a value of 0.06 WBE/mL (Table 3).
These results indicate that the extracts keep similar
antibacterial spectrum to ramoplanins.
Inhibition Peptidoglycan Biosynthesis
All extracts tested for inhibition of macromolecular labeling
exhibited specific activity by inhibiting peptidoglycan synthesis
(PG) above 80%. Figure 3 illustrates an example of the labeling
test of one of the active extracts from the NP screening in
a two-fold serial dilution series for inhibition of DNA and
peptidoglycan syntheses in B. subtilis HB0950. This sample
inhibited PG to a greater extent than they inhibited protein or
DNA syntheses, indicating that it is a selective inhibitor of PG
synthesis.
Chemical Analysis of LiaRS Positive
Extracts
All extracts that were confirmed hits in the LiaRS screen
were analyzed by HR-LCMS. Since ramoplanin was a known
compound active in this assay, sample dereplication was
performed in order to eliminate those samples containing
this molecule from undergoing further isolation efforts. High
resolution mass spectrometry signatures of each extract were
evaluated and scanned for single ions corresponding to doubly
charged species of ramoplanin A1, A2, and A3. In addition, the
presence of ramoplanoses A1, A2, and A3, glycosylated versions
of the ramoplanins, was also observed (Figure 4). Further,
FIGURE 3 | Dose-Response curves from the Labeling test of one of the
active extracts from the NP screening in B. subtilis HB0950.
some additional ramoplanin analogs were also identified. These
analogs corresponded to reduced versions (+4H and +O,4H)
of ramoplanins, with the modifications presumably occurring
in the N-acyl hydrophobic sidechain. All extracts showed mass
spectrometry signatures (range of molecular weights and isotopic
distributions) that confirmed the presence of compounds related
to ramoplanin structural family and within them new analog
compounds.
DISCUSSION
Ramoplanin is a suitable clinical candidate for the treatment
of infections caused by aerobic or anaerobic Gram-positive
pathogens (Farver et al., 2005). The mechanism of action of
ramoplanin makes it unlikely that it will develop high levels
of resistance since this compound acts on the second phase of
peptidoglycan biosynthesis, capturing the Lipid intermediate II
(Somner and Reynolds, 1990).
Thus, far, ramoplanin was only isolated from the fermentation
of a strain of Actinoplanes sp. ATCC 33076 (Farver et al., 2005).
However, in this study we have found 49 distinct actinomycete
strains producing compounds related to this antibiotic. Further,
our findings demonstrate that the extracts prepared from
this group of strains display antibacterial profiles similar to
ramoplanin.
These extracts revealed a positive response to the agar
diffusion assay developed from studies in Cornell University
(Mascher et al., 2003, 2004) showing activity against B. subtilis
strains HB0950 and HB0953, being that they revealed a blue ring
(X-Gal hydrolysis by the presence of β-galactosidase) in the strain
containing the P liaI-lacZ fusion and they did not show such a
response in the strain that additionally contained a gene insertion
of kanamycin resistance in the liaR gene. Extracts positive in this
test proved to be compounds that specifically interfere with the
Lipid II as ramoplanin does (Mascher et al., 2004).
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FIGURE 4 | HPLC and High Resolution LC-MS spectrum profile of some of the actives from the natural products screening which matched with
Ramoplanin A2 and Ramoplanose. (Extract example: F-151,222-C01-C01). (A1): UV-visible trace; (A2): TIC (Total ion chromatogram); (B): UV-visible spectra at
4.49min; (C): Mass spectra at 3.74min from FTMS positive ion; (D1): Mass spectra at 3.74min. (D2): Theoretical isotopic distribution of Ramoplanose A2.
Moreover, most of them exhibited specific activities against
Gram-positive bacteria (S. aureus, E. faecalis), as shown
in Table 3. Also, all the extracts completely and selectively
inhibited peptidoglycan biosynthesis, as demonstrated
by the results obtained in a macromolecular labeling
assay.
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Analysis of the extracts by HR-LCMS indicated that they
all contained compounds that belong to ramoplanin family.
Dereplication was able to quickly identify these components
and eliminated the need for extensive isolation efforts. Scale-up
of selected cultures and isolation of novel ramoplanin analogs
identified is in progress.
The point that most of the producing organisms belong to
the Micromonosporaceae family is consistent with the taxonomy
of the original organism producer of ramoplanin (Farver et al.,
2005). Our results additionally suggest that the production of
ramoplanin analogs is widespread within the actinomycetes.
Geographically, the producers of these compounds were
dispersed throughout the whole world based on the different
origin of the samples from which the strains of our study came
from.
The results obtained in this study support the fact that natural
products are an unlimited source of potential drugs, in particular
of antibiotics (Peláez, 2006; Chopra, 2013; Lacret et al., 2015;
Ling et al., 2015; Crespo et al., 2016). They also demonstrate
the power of using novel screening strategies that combine new
knowledge in biotechnology with libraries of natural products in
order to find new drug candidates against multi-drug resistance
pathogens.
Our data strongly suggest the presence of new ramoplanin-
analogs among the actinomycete strains of this study, so large
scale fermentations and purifications of selected strains are being
currently performed in order to identify these new antimicrobials
which perhaps could overcome the low local tolerability of
ramoplanin when injected intravenously.
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